Antibody Shows Promise Against Obesity-related Liver Disease and Atherosclerosis in Mice
October 28, 2024 / Obesity Treatment / MASH / Liver Disease / Insulin Sensitivity / Liver Health
The antibody bFKB1 shows promise for treating obesity-related liver disease and atherosclerosis in mice by improving inflammation, insulin sensitivity, and liver function, potentially paving the way for a new therapeutic for MASH.
Cardiometabolic risk factor clusters in older adults using latent class analysis on the Bushehr elderly health program
October 28, 2024 / Metabolic Syndrome in Elderly / Cardiometabolic Risk
Using latent class analysis, this study identified four distinct cardiometabolic risk clusters among Iranian older adults with metabolic syndrome, highlighting the potential for tailored risk management to mitigate cardiovascular and metabolic disease progression in this population.
“Complex Interplay Between T2D and MASH: Key Drivers and Emerging Treatment Strategies “
October 28, 2024 / MASH Diabetes Management / Insulin Resistance / Liver Disease / T2D
A recent study highlights that metabolic-associated steatohepatitis (MASH) management in diabetes involves lifestyle changes, weight loss, and pharmacological strategies, targeting visceral fat, insulin resistance, and gut dysbiosis to prevent progression.
Development of shoulder osteoarthritis and bone lesions in female and male rats subjected to a high fat/sucrose diet
October 28, 2024 / High-fat Diet / Prebiotic Fiber Joint Health
A high-fat/sucrose diet (HFS) led to shoulder joint degeneration in male but not female rats, with prebiotic fiber reducing damage in males. This suggests sex-specific dietary impacts on joint health and potential protective roles for fiber.
Dynamics of the human bile acid metabolome during weight loss
October 28, 2024 / Bariatric Surgery Bile Acids / Weight Loss / Metabolic Disease Intervention
Bariatric surgery induces distinct, sustained changes in bile acid profiles that differ significantly from low-calorie diets, highlighting specific bile acids as potential therapeutic targets for metabolic disease intervention.
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
October 28, 2024 / Fractyl Health / Weight Managemtn / ObesityWeek 2024 / Gene Therapy
Fractyl Health will present data at ObesityWeek 2024 showing sustained weight maintenance from its Revita® and Rejuva® platforms, which aim to address obesity and T2D by targeting root metabolic dysfunction through duodenal resurfacing and gene therapy approaches.
GLP-1 Drugs For Obesity Treatment Reduce Bariatric Surgeries By 25%: Study
October 28, 2024 /GLP-1 Obesity Treatment / Bariatric Surgery Decline / Weight Loss Drugs vs Surgery / Weight Management
GLP-1 drugs for obesity treatment have led to a 25.6% decrease in bariatric surgeries, with prescriptions doubling from 2022 to 2023, signaling a shift in weight management strategies.
Weight-loss surgery down 25 percent as anti-obesity drug use soars
October 28, 2024 / Anti-obesity Drug Trends / GLP-1 Receptor / Weight-loss Treatment
A study shows GLP-1 RA drug use for obesity treatment has more than doubled, resulting in a 25.6% decline in bariatric surgery among insured patients. Researchers emphasize balanced access to both surgical and pharmacologic obesity treatments.
Fatty liver disease alarms health experts
October 27, 2024 / Metabolic Fatty Liver Disease / MAFLD / Philippines / Liver Health / Cholesterol / Silent Liver Diease
Experts warn of rising metabolic-associated fatty liver disease (MAFLD) among Filipinos, now affecting individuals as young as 30, often linked to high cholesterol levels.
The importance of muscle preservation in medically induced weight loss
October 26, 2024 / Muscle Loss / Weight Loss / GLP-1 Agonist / Obesity Treatment / Muscle Health / Obesity Risk
A Lancet commentary emphasizes preserving muscle during GLP-1 agonist-induced weight loss, as significant muscle loss can impact immunity, metabolic health, and physical function. Combining medication with exercise and nutrition can mitigate these risks.
CGMs Aren’t Just for People with Diabetes Anymore, Dexcom COO Says
October 25, 2024 / Stelo CGM non-diabetic use / Dexcom Glucose Monitoring / Metabolic Health / Preventive Diabetes Management
Dexcom’s Stelo CGM, now available over-the-counter, allows individuals without diabetes to monitor glucose levels, fostering metabolic health awareness and potentially preventing progression to diabetes. Dexcom aims to expand access and affordability.
Components of Metabolic Syndrome Increase All-Cause, Vascular Dementia Risks
October 25, 2024 / Metabolic Syndrome Dementia Risk / Vascular Dementia / Obesity
Metabolic syndrome components elevate risks for all-cause and vascular dementia but not Alzheimer’s disease, with obesity and hyperglycemia as primary risk factors. Lifestyle management of metabolic syndrome may support dementia prevention efforts.
Identification of metabolic biomarkers in idiopathic pulmonary arterial hypertension using targeted metabolomics and bioinformatics analysis
October 25, 2024 / IPAH Metabolic Biomarkers / Biomarkers
This study identifies five metabolites and three genes as potential biomarkers for diagnosing idiopathic pulmonary arterial hypertension (IPAH), revealing significant metabolic alterations, particularly in the arginine biosynthesis pathway, that could aid early detection.
Metabolic Risk Contributes to Diabetes Onset in People With HIV
October 25, 2024 / HIV and Diabetes Risk / HIV Management / Metabolic Syndrome / Diabtes / Metabolic Health
In HIV-positive individuals with low-to-moderate ASCVD risk, metabolic factors like high BMI and prediabetes significantly contribute to diabetes onset, even with statin use, highlighting the need for metabolic risk management.
Incidence and risk factors of post-metabolic and bariatric surgery hypoglycemia: a systematic review
October 24, 2024 / Post-bariatric Surgery / Gastric Bypass Risk / MBSH Risk Factors / Metabolic Surgery Complications
Post-bariatric surgery hypoglycemia (MBSH) is most prevalent in younger women after Roux-en-Y gastric bypass with significant weight loss. Prior cholecystectomy, antidepressant use, and glucose variability are key risk factors for MBSH.
Subclassification of obesity for precision prediction of cardiometabolic diseases
October 24, 2024 / Obesity / Cardiometabolic Risk Prediction / Obesity / BMI Health
This study identifies five unique obesity subtypes with cardiometabolic risks that differ from BMI-based expectations. Incorporating these “”discordant”” profiles improves precision in predicting and preventing cardiometabolic diseases, potentially enhancing individualized obesity management.
Common PCOS treatments do not increase, decrease metabolic syndrome risk
October 22, 2024 / PCOS / Metabolic Syndrome Risk / Oral Contraceptives
Neither low-dose contraceptives nor metformin reduced metabolic syndrome prevalence in women with PCOS and elevated BMI. Findings indicate these treatments may need reevaluation for CVD risk management in PCOS patients.
Having a ‘sweet tooth’ may raise risk of conditions like depression and diabetes
October 22, 2024 / Sweet Tooth Health Risks / Depression / Chronic Disease Risk / Metabolic Benefits
People with a “”sweet tooth”” face increased risks of depression, diabetes, and stroke, while health-conscious diets may offer protective metabolic benefits. Limiting free sugars can support better long-term health outcomes.
Time-restricted eating for metabolic syndrome
October 22, 2024 / Metabolic Syndrome / Intermittent Fasting / Blood Glucose Control
Time-restricted eating improves metabolic syndrome markers, including blood glucose and body weight, among adults with prediabetes. This lifestyle change shows promise for metabolic health but requires further long-term studies to confirm effects.
Ultra-processed foods linked to liver disease and insulin resistance in obese children
October 22, 2024 / Liver Disease / Childhood Obesity / Insulin Resistance / Pediatric Metabolic Disorders / MASLD
A study links ultra-processed food consumption among obese children to higher rates of insulin resistance and metabolic-associated liver disease (MASLD), underscoring concerns over ultra-processed foods in pediatric obesity and metabolic health.